Robert W. Baird Maintains Buy Rating on Irhythm Technologies with $160 Price Target

Irhythm Technologies received a Buy rating from Robert W. Baird with a price target of $160.00. David Rescott, a 4-star analyst, maintained the rating and has a 53.08% success rate. In addition, BTIG's Marie Thibault also gave a Buy rating, while TR | OpenAI reiterated a Hold rating. The company's market cap is $4.43B and has a P/E ratio of -42.69. Corporate insider sentiment is negative, with an increase in insider selling.

iRhythm Technologies, Inc. (NASDAQ: IRTC), a digital healthcare company specializing in ambulatory cardiac monitoring services, has seen a shift in analyst ratings and market dynamics. The company received a Buy rating from Robert W. Baird with a price target of $160.00 [3]. David Rescott, a 4-star analyst, maintained the rating and has a 53.08% success rate [3]. Additionally, BTIG's Marie Thibault also gave a Buy rating, while TR | OpenAI reiterated a Hold rating [3]. The company's market capitalization stands at $4.43 billion, with a P/E ratio of -42.69 [3].

Corporate insider sentiment has been negative, with an increase in insider selling. In the last quarter, insiders sold 5,356 shares of company stock valued at $796,882. This represents 0.68% of the stock owned by insiders [3].

iRhythm Technologies has been in the spotlight due to regulatory issues and a securities class action lawsuit. In May 2023, the company received a Warning Letter from the FDA regarding non-conformities to regulations for medical devices, including medical device reporting requirements, relating to the Company's Zio AT System [2]. The company and certain of its executives were subsequently sued in a securities class action lawsuit, charging them with failing to disclose material information during the Class Period [2]. The court denied the Company's motion to dismiss the case, allowing it to continue [2].

Despite these challenges, the company has seen a reduction in its price target by stock analysts. Morgan Stanley reduced its price target from $160.00 to $147.00, indicating a potential upside of 5.89% from the stock's current price [3]. Other brokerages, such as Citigroup and Needham & Company LLC, have also issued reports on IRTC, with varying ratings and price targets [3].

Investors should closely monitor the regulatory and legal developments surrounding iRhythm Technologies, as well as the evolving analyst ratings and market dynamics. The company's ability to navigate these challenges will be crucial in determining its future performance.

References
1. [https://finance.yahoo.com/quote/IRTC/](https://finance.yahoo.com/quote/IRTC/)
2. [https://www.morningstar.com/news/pr-newswire/20250711da28924/irhythm-investigation-continued-by-former-louisiana-attorney-general-kahn-swick-foti-llc-continues-to-investigate-the-officers-and-directors-of-irhythm-technologies-inc-irtc](https://www.morningstar.com/news/pr-newswire/20250711da28924/irhythm-investigation-continued-by-former-louisiana-attorney-general-kahn-swick-foti-llc-continues-to-investigate-the-officers-and-directors-of-irhythm-technologies-inc-irtc)
3. [https://www.marketbeat.com/instant-alerts/irhythm-technologies-nasdaqirtc-given-new-14700-price-target-at-morgan-stanley-2025-07-15/](https://www.marketbeat.com/instant-alerts/irhythm-technologies-nasdaqirtc-given-new-14700-price-target-at-morgan-stanley-2025-07-15/)